Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is beginning to pay off. Novo scored an approval on Monday for nedosiran, an RNAi therapy developed by Dicerna to treat a rare kidney disease called primary hyperoxa…

Comments

You must log in or register to comment.

(._.)

There's nothing here…

1 point (+1, −0)

Short URL:

http://blurb.social/67938

Business

Welcome to /f/business! This blurb is dedicated to business news and discussions. Whether you're an entrepreneur, investor, or simply interested in the latest developments in the business world, you've come to the right place. Share and discuss market trends, financial news, industry insights, startups, and more.

Our basic rules ensure a constructive and respectful community:

Be respectful: Maintain a civil tone, avoid personal attacks, and refrain from using derogatory language.
Stay on topic: Keep posts and comments relevant to business news and related topics.
Provide reliable sources: Cite credible sources whenever possible to foster informed discussions.
Avoid self-promotion: Contribute valuable insights rather than excessively promoting yourself or your business.
No financial or investment advice: Seek professional advice and avoid considering shared information as expert advice.

Use the upvote and downvote buttons to highlight quality content and maintain engagement. Enjoy your time here and contribute to the ever-evolving world of business news!

Created June 22, 2023
Subscribe via RSS

Moderators

joeyrobert

See full list